ReviewBioengineered2021
Sophorolipid: a glycolipid biosurfactant as a potential therapeutic agent against COVID-19.
Review in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 48 citations in OpenAlex.
- Biosurfactant-Based Interventions for Improving Lung Function and Controlling Inflammation.Pharmaceutical research · 2026Review
- Functional Implications of Marine Biosurfactants and Their Therapeutic Potential Against Alzheimer's Disease.Food science & nutrition · 2026Review
- Antiviral Potential of Lipopeptide Biosurfactant Isolated from Acinetobacter junii B6.Iranian biomedical journal · 2026Article
- Overcoming Candida albicans biofilm drug resistance via azole-sophorolipid synergy.Scientific reports · 2026Article
- Sugar Esters of Fatty Acids: Chemo-Enzymatic Synthesis and Biological Activity.Molecules (Basel, Switzerland) · 2025Review
- Elucidating a novel metabolic pathway for enhanced antimicrobial glycolipid biosurfactant production in the yeast Meyerozyma guilliermondii.Scientific reports · 2025Article
- Sophorolipids as anticancer agents: progress and challenges.Discover oncology · 2025Review
- Exploring Biosurfactants as Antimicrobial Approaches.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Application of Biosurfactants in Medical Sciences.Molecules (Basel, Switzerland) · 2024Review
- Microbial Biosurfactants: Antimicrobial Activity and Potential Biomedical and Therapeutic Exploits.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Sustainable biosurfactant production from secondary feedstock-recent advances, process optimization and perspectives.Frontiers in chemistry · 2024Review
- Harnessing the Potential of Biosurfactants for Biomedical and Pharmaceutical Applications.Pharmaceutics · 2023Review
- Carbon and nitrogen optimization in solid-state fermentation for sustainable sophorolipid production using industrial waste.Frontiers in bioengineering and biotechnology · 2023Article
- Biotechnological potential of microbial bio-surfactants, their significance, and diverse applications.FEMS microbes · 2023Review
- Microbial biosurfactants: a review of recent environmental applications.Bioengineered · 2022Review
- Apigenin analogues as SARS-CoV-2 main protease inhibitors:Bioengineered · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biosurfactants are natural surfactants produced by a variety of microorganisms. In recent years, biosurfactants have garnered a lot of interest due to their biomedical and pharmaceutical applications. Sophorolipids are glycolipid types of biosurfactants produced by selected nonpathogenic yeasts. In addition to the detergent activity (reduction in surface and interfacial tension), which is commonly utilized by biomedical applications, sophorolipids have shown some unique properties such as, antiviral activity against enveloped viruses, immunomodulation, and anticancer activity. Considering their antiviral activity, the potential of sophorolipids as an antiviral therapy for the treatment of COVID-19 is discussed in this review. Being a surfactant molecule, sophorolipid could solubilize the lipid envelope of SARS-CoV-2 and inactivate it. As an immunomodulator, sophorolipid could attenuate the cytokine storm caused by the SARS-CoV-2 upon infection, and inhibit the progression of COVID-19 in patients. Sophorolipids could also be used as an effective treatment strategy for COVID-19 patients suffering from cancer. However, there is limited research on the use of sophorolipid as a therapeutic agent for the treatment of cancer and viral diseases, and to modulate the immune response. Nevertheless, the multitasking capabilities of sophorolipids make them potential therapeutic candidates for the bench-to-bedside research for the treatment of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.